Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
26.00
+7.50 (40.54%)
At close: Nov 13, 2025
TEVJF Revenue
Teva Pharmaceutical Industries had revenue of $4.48B in the quarter ending September 30, 2025, with 3.42% growth. This brings the company's revenue in the last twelve months to $16.78B, up 0.02% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
16.78B
Revenue Growth
+0.02%
P/S Ratio
1.84
Revenue / Employee
482.22K
Employees
35,686
Market Cap
30.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
Teva Pharmaceutical Industries News
- 3 days ago - Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - GlobeNewsWire
- 7 days ago - Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December - GlobeNewsWire
- 9 days ago - Teva seeks startups to help solve global pharmaceutical challenges - Reuters
- 10 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA) - GuruFocus
- 14 days ago - Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business - Seeking Alpha
- 17 days ago - Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock - Benzinga
- 18 days ago - Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 - The Motley Fool